Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

Inclusion Criteria: * Recipients of allogeneic bone marrow, cord blood, or peripheral blood stem cell transplants are eligible * Age \>6 years and able to complete pulmonary function testing * Patients with evidence of sub-acute, non-infectious pulmonary dysfunction (OLD or RLD) * Recipients of sub-ablative transplant regimens are eligible * Recipients of donor leukocyte infusions (DLI) post-transplant are eligible * Patients must be \> 100 days post transplant Exclusion Criteria: * Patients with hypotension requiring inotropic agents other than dopamine \< 5mcg/ kg/ minute for blood pressure support. * Patients with a positive quantitative bacterial culture from the BAL fluid (≥ 104 CFU/ ml is considered positive) * Patients whose BAL fluid is positive for significant bacterial pathogens or pathogenic nonbacterial microorganisms (as defined by protocol) by special stain, culture or PCR analysis * Patients who are enrolled on a phase I or phase II trial for the prophylaxis or treatment of GVHD (acute or chronic) within 7 days of study entry. * Patients with known hypersensitivity to etanercept. * Patients who are pregnant. * Patients with CMV seropositivity at the time of study entry. Testing may include wither CMV PCR analysis or CMV pp65 testing. * Evidence for multi-system organ failure.